New Risk Assessment Tool in Beta Testing

A new psychometric assessment tool to evaluate a patients risk of medication abuse or diversion is in beta testing at 8 pain management centers nationwide. Developed by VeriMed, Inc., RADARsm, or Risk Assessment of Diversion and Aberrancy is the first to provide prescribing clinicians with a window into the likelihood of deceptive or manipulative behavior—traits that the company believes are predictors of diversion. Read a press release announcing the launch here.


Related Content